ruxolitinib + rineterkib

**Ruxolitinib + rineterkib** is an investigational oral combination therapy under clinical evaluation for the treatment of myelofibrosis in patients with suboptimal response to ruxolitinib alone. Ruxolitinib is a selective inhibitor of Janus kinase 1 and 2 (JAK1/JAK2), disrupting cytokine signaling implicated in myeloproliferative neoplasms. Rineterkib (LTT462) is a small-molecule inhibitor of extracellular signal-regulated kinase 1 and 2 (ERK1/2), enzymes involved in the MAPK pathway critical for the survival of JAK-mutated clones driving myelofibrosis. The combination targets parallel signaling pathways with the aim to deliver a more robust disease-modifying effect for patients with myelofibrosis. The most recent clinical activity has been in a phase 1b/2 open-label, multicenter platform study (ADORE; NCT04097821), sponsored by Novartis, with primary endpoints examining safety, tolerability, and pharmacokinetics. The trial was terminated after phase 1[1][2][3][5].

Brand names

Jakafi (for ruxolitinib)

Other names

ruxolitinib + LTT462